Related Experiment Video
Updated: Feb 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Pacemaker-associated thrombosis in ongoing therapy with edoxaban tosylate
Angelo Di Vincenzo1, Alessandro Rizzo2, Lucia Russo3
1Internal Medicine 3, University Hospital of Padova, Via Giustiniani 2, 35128, Padua, Italy. divincenzoang@gmail.com.
Pacemaker implantation can cause thromboembolism, even with anticoagulant therapy. This case highlights that continuous edoxaban did not prevent pacemaker lead thrombosis, suggesting current prophylaxis strategies may be insufficient.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Thromboembolism is a recognized complication following pacemaker implantation.
- Antithrombotic prophylaxis is not routinely used for preventing pacemaker lead-associated thrombosis.
Observation:
- A patient undergoing continuous oral anticoagulant therapy with edoxaban developed pacemaker lead-associated thrombosis.
- Existing literature lacks data on anticoagulant prophylaxis for pacemaker lead thrombosis.
Findings:
- Continuous edoxaban treatment was ineffective in preventing pacemaker lead thrombosis in this patient.
- Three-dimensional transthoracic echocardiography aided in the diagnostic assessment of thrombosis.
Implications:
- Current clinical practices for pacemaker implantation may require re-evaluation regarding thrombotic event prevention.
- Further research is needed to establish effective prophylactic strategies for pacemaker lead thrombosis, especially in patients on anticoagulation.
Related Concept Videos
Venous Thrombosis I: Introduction
Gene Therapy
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Group Therapy
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

